相关临床试验
7
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
6
85.7%
已完成
1
14.3%
暂无批准数据
- DelveInsight's 2025 pipeline report reveals over 20 pharmaceutical companies are actively developing 22+ interleukin-2 inhibitor drugs across various clinical stages. - The FDA granted fast track designation to rezpegaldesleukin for moderate to severe atopic dermatitis in February 2025, while nemvaleukin development was discontinued following failed Phase III trial results. - Leading pipeline candidates include Soquelitinib in Phase III for relapsed/refractory PTCL and multiple Phase II programs targeting autoimmune diseases and cancer indications. - The growing prevalence of autoimmune diseases and organ transplant procedures is driving increased demand for IL-2 inhibitors due to their role in preventing immune rejection.
- The MIROCALS clinical trial demonstrated that low-dose interleukin-2 (IL2LD) is safe and reduced the risk of death by over 40% in approximately 80% of motor neurone disease patients with lower levels of a specific biomarker. - The groundbreaking study provides compelling evidence that modifying the immune system could be an effective strategy for altering MND/ALS progression, potentially adding to the disease-modifying effects of riluzole. - While not yet licensed for MND treatment, IL2LD increases regulatory T cells to reduce inflammation, and ILTOO Pharma has secured exclusive licensing rights to pursue regulatory approval for this novel therapeutic approach.
